Research graph
References from Association of Adjuvant Immunotherapy With Survival Outcomes Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Immunochemotherapy: A Propensity Score-Matched Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention
10.1038/s41571-023-00747-0 · 2023 · External reference
Unresolved reference
2026 · External reference
PRODIGY: A phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer
10.1200/jco.20.02914 · 2021 · External reference
Peri/post-operative chemotherapy of oxaliplatin combined with S-1 (SOX) versus post-operative oxaliplatin with capecitabine (XELOX) in locally advanced gastric cancer: RESOLVE Trial
2017 · External reference
Pembrolizumab plus chemotherapy versus chemotherapy as perioperative therapy in locally advanced gastric and gastroesophageal junction cancer: Final analysis of the randomized, phase III KEYNOTE-585 study
10.1200/jco-25-00486 · 2025 · External reference
Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy
10.1001/jamanetworkopen.2022.5557 · 2022 · External reference
Downstaging effect rather than the full intended cycles of perioperative chemotherapy determines the value of adjuvant chemotherapy in gastric cancer
10.1245/s10434-024-16365-8 · 2024 · External reference
Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse event: A case report
10.2217/imt-2021-0085 · 2021 · External reference
Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
2023 · External reference
Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance
10.1038/s41571-019-0218-0 · 2019 · External reference
Tumor microenvironment can promote cancer cell invasion and foster immune suppression
10.62051/t3xjpc97 · 2024 · External reference
Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics
10.1016/j.drup.2024.101080 · 2024 · External reference
Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
10.1016/j.annonc.2021.02.004 · 2021 · External reference
Unresolved reference
2017 · External reference
Prognostic impact of immune-related adverse events with nivolumab in patients with advanced gastric cancer: A multicenter retrospective analysis
2020 · External reference
Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: A propensity score matching analysis
10.1007/s00464-023-10052-7 · 2023 · External reference
Short- and long-term outcomes following perioperative ERAS management in patients undergoing minimally invasive radical gastrectomy after neoadjuvant chemotherapy: A single-center retrospective propensity score matching study
10.1016/j.ejso.2024.109459 · 2025 · External reference
Randomized controlled trial comparing the short-term outcomes of Enhanced Recovery After Surgery and conventional care in laparoscopic distal gastrectomy (GISSG1901)
10.1097/sla.0000000000004908 · 2021 · External reference
Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey
10.1097/01.sla.0000133083.54934.ae · 2004 · External reference
Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology
10.6004/jnccn.2022.0008 · 2022 · External reference
The association of survival with adjuvant chemotherapy in patients with ypTNM stage I gastric cancer after neoadjuvant chemotherapy
10.1186/s12957-026-04224-7 · 2026 · External reference
Effect of adjuvant chemotherapy cycles on patients with node-negative gastric cancer following neoadjuvant chemotherapy: Multicenter cohort study
10.1245/s10434-024-16585-y · 2025 · External reference
Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy
10.1001/jamanetworkopen.2022.5557 · 2022 · External reference
Optimizing surgical timing following neoadjuvant therapy for gastric cancer: Insights from a multicenter retrospective analysis
2025 · External reference
Predictive biomarkers in the era of immunotherapy for gastric cancer: Current achievements and future perspectives
2025 · External reference
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial
10.1200/jco.2011.39.1953 · 2012 · External reference
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial
10.1200/jco.2010.33.0597 · 2011 · External reference
Predictive biomarkers for immunotherapy in gastric cancer: Current status and emerging prospects
10.3390/ijms242015321 · 2023 · External reference
Immune checkpoint inhibitors: Breakthroughs in cancer treatment
10.20892/j.issn.2095-3941.2024.0055 · 2024 · External reference
Immune checkpoint therapy—current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023 · External reference
Therapeutic targets and biomarkers of tumor immunotherapy: Response versus non-response
10.1038/s41392-022-01136-2 · 2022 · External reference
Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer
2025 · External reference
Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer
2022 · External reference
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
10.1186/s40364-022-00413-0 · 2022 · External reference
Dissecting response and resistance to anti–PD-1 therapy in microsatellite-unstable gastric cancer
10.1158/2159-8290.cd-21-0857 · 2021 · External reference
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
10.1186/s13045-022-01242-2 · 2022 · External reference
Immune-checkpoint inhibitors: Long-term implications of toxicity
10.1038/s41571-022-00600-w · 2022 · External reference
Unresolved reference
2025 · External reference
KEYNOTE-585 fails while Matterhorn succeeds in gastric cancer: What lessons can we learn?
10.1200/jco-25-01439 · 2025 · External reference
